TENAYA THERAPEUTICS INC reports a Return on Equity (ROE) of -78.17%.

What is TNYA's dividend yield?

TENAYA THERAPEUTICS INC offers a dividend yield of 0.00%.

What is TNYA's Quality Score?

Our AI rates TNYA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy TNYA?

Our AI Timing Score for TNYA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does TNYA belong to?

TENAYA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

TNYA (NASDAQ) Stock Analysis | TENAYA THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

TNYA AI Analysis Summary

Our AI summary for TNYA: TENAYA THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -78.17%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TNYA

TENAYA THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 91

USD 0.74

-0.01 (-1.29%) Day Change

Watchlist Portfolio Compare Chart

0.03

D/E

-78.2%

ROE

-61.5%

ROA

0.00%

Div Yield

TENAYA THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.74 Price -0.01 (-1.29%) Day Change	NEWS SCORE: 91

TNYA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.74
PBV / Sector	1.53 / 5.20 GOOD
Earning Per Share	-0.38

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	2.10 M GREAT
Average 1W Daily Value	1.19 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-36,891.11 / 98.71
NPM Average (%) / Sector	-36,891.11 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-61.45 / 27.02
ROA Average (%) / Sector	-66.57 / -368.17
ROA Change Average (%) / Sector	14.42 / 5,404.12 GOOD
ROE (%) / Sector	-78.17 / 3.47
ROE Average (%) / Sector	-82.23 / 6.51
ROE Change Average (%) / Sector	19.35 / 2,128.13 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:35
Symbol	TNYA
Name	TENAYA THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	217.00 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	162.75 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Phone: 650 825 6990

Website: https://www.tenayatherapeutics.com

Employees: 70

Sector: Healthcare >> Biotechnology

Description: Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.